NeuDirection’s Neu-001 Successfully Completes Phase I Clinical Trial
NeuDirection announces that its innovative drug Neu-001 for the treatment of amblyopia has successfully completed its Phase I clinical trial. The trial results demonstrated favorable safety and tolerability profiles, establishing a solid foundation for further clinical development. Neu-001 is a…